Dr. Lee Kaplan took the stage with an urgent message, telling fellow physicians they have a powerful weapon to fight the ...
Britain prevents Ozempic reaching people who want to lose weight because of a national semaglutide shortage. But some pay ...
As doctors in the United States scale back their prescription of opioid painkillers, a new option for hard-to-treat pain is taking root: ketamine, the decades-old surgical drug that is now a ...
Whether for weight loss or diabetes management, Canadian pharmacists say demand for Ozempic prescriptions does not appear to be slowing, despite a proposed lawsuit over alleged side effects.
Prescriptions for semaglutide jumped 150% in the past year, with an 80% increase in prescriptions written per provider, new data suggest. Among more than 350,000 prescribers in the nationwide ...
Despite widely publicized reports of rare but severe side effects, obesity doctors say Ozempic and drugs like it have the potential to improve medical help for a chronic illness that patients ...
Semaglutide injectables like Ozempic, Wegovy and Mounjaro have revolutionized how doctors treat diabetes and obesity. The drug has become a popular weight-loss tool, buoyed by its popularity among ...
It’s unusual for a medication to become a household name; even more uncommon for its branding to become, like Advil, shorthand for an entire class of products; and rarest of all, for it to ...
Over the past century, many medical breakthroughs — such as penicillin, the polio vaccine and the birth control pill — have had a huge impact on society. But few can say they had their own ...
Glen Patton says he's not one to panic. But a global shortage of the diabetes drug Ozempic has diabetics like him rattled — he says access to the medication could mean the difference between ...
Trish Webster, 56, was prescribed Ozempic to help her squeeze into her dream dress for her daughter’s nuptials. Ozempic is a medication approved by the US Food and Drug Administration for people ...
Drugmakers Eli Lilly and Novo Nordisk both reported strong third-quarter sales growth Thursday, citing the performance of the GLP-1 class of diabetes and anti-obesity drugs that are in high demand.
